Gepirone ER “not approvable” for third time
Executive Summary
FDA deems Fabre-Kramer Pharmaceuticals' gepirone ER "not approvable" for treatment of adults with major depressive disorder, firm says Nov. 2. FKP submitted an amendment to the NDA for the potential first-in-class 5HT1a agonist in May with data that FDA requested in a 2004 "not approvable" notice received by then-licensee Organon. The drug was to be marketed by GlaxoSmithKline under an agreement inked by the companies in February. The partners said they are evaluating FDA's response "to determine appropriate next steps." FKP reacquired rights to gepirone ER from Organon in 2005. Organon had withdrawn its application for the drug after receiving two "not approvable" letters, in 2002 and 2004 (1"The Pink Sheet" June 28, 2004, In Brief)...
You may also be interested in...
Organon to withdraw gepirone NDA
Organon is planning to withdraw the NDA for its antidepressant gepirone ER following the receipt of a second "not approvable" letter from FDA June 23. The company submitted additional data in December 2003, and planned to market the drug as Variza. FDA's response likely relates to efficacy concerns, which were cited in the first "not approvable" letter in April 2002. Organon had been counting on gepirone (along with the contraceptive Implanon) as one of two major launches in 2004 (1"The Pink Sheet" April 26, 2004, p. 15)...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.